(Q46458158)

22 December 2017

title

Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece (English)

1 reference

22 December 2017

1 reference

1 reference

Georgia Kourlaba

1

1 reference

22 December 2017

Vassilis Fragoulakis

series ordinal

2

1 reference

22 December 2017

Nikos Maniadakis

series ordinal

3

1 reference

22 December 2017

publication date

1 September 2012

1 reference

22 December 2017

Applied Health Economics and Health Policy

published in

1 reference

22 December 2017

volume

10

1 reference

22 December 2017

issue

5

1 reference

22 December 2017

page(s)

331-342

1 reference

22 December 2017

https://scigraph.springernature.com/pub.10.1007/bf03261867

exact match

0 references

cites work

Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Multi-bed vascular disease and atherothrombosis: scope of the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Optimal medical therapy with or without PCI for stable coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Clopidogrel versus aspirin in patients with atherothrombosis: CAPRIE-based calculation of cost-effectiveness for Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Validity of the EuroQoL (EQ-5D) instrument in a Greek general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Analysis of cost data in randomized trials: an application of the non-parametric bootstrap

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Definition, interpretation and calculation of cost-effectiveness acceptability curves.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Cost-effectiveness versus cost-utility analysis of interventions for cancer: does adjusting for health-related quality of life really matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angiop

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03261867

21 January 2018

Identifiers

DOI

10.1007/BF03261867

1 reference

22 December 2017

1 reference

22 December 2017